cladribine has been researched along with Lymphoma, Non-Hodgkin in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 37 (61.67) | 18.2507 |
| 2000's | 18 (30.00) | 29.6817 |
| 2010's | 4 (6.67) | 24.3611 |
| 2020's | 1 (1.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Dong, T; Ji, J; Kuang, P; Li, J; Liu, J; Liu, T; Liu, Z; Shen, K; Zhang, C; Zhang, L | 1 |
| Adamia, S; Ciccarelli, BT; Ghobrial, IM; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Leleu, X; Manning, R; Moreau, AS; Patterson, CJ; Roccaro, A; Sacco, A; Soumerai, J; Treon, SP | 1 |
| Miller, HJ; Saven, A; Schram, ED; Sigal, DS | 1 |
| Hotta, T; Kinoshita, T; Kosugi, H; Kusumoto, S; Matsuda, S; Motoji, T; Nagai, H; Ogura, M; Ohnishi, K; Ohyashiki, K; Omachi, K; Takahashi, N; Takayama, N; Yamaguchi, M | 1 |
| Aguilar, J; Al-Katib, A; del Busto, R; Johnson, LB; Obeid, KM; Sharma, M; Szpunar, S | 1 |
| Acker, T; Berghoff, M; Dassinger, B; Gizewski, ER; Grams, A; Hildebrandt, GC; Kaps, M; Klappstein, G; Schänzer, A | 1 |
| Bergmann, L; Burkhard, O; Chow, KU; Hansmann, ML; Hoelzer, D; Jäger, E; Karakas, T; Mezger, J; Mitrou, PS; Ritzel, H; Rummel, MJ; Schalk, KP; von Grünhagen, U | 1 |
| Baudo, F; deCataldo, F | 1 |
| Ogura, M | 1 |
| Alves, AC; Bordin, JO; Colleoni, GW; de Oliveira, JS; de Souza, VA; Duarte, LC; Kerbauy, FR; Lobão, M; Yunis, MP | 1 |
| Höfler, G; Jäger, G; Linkesch, W; Neumeister, P | 1 |
| Armitage, JO; Hoelzer, D; Rummel, MJ; Tobinai, K | 1 |
| Chou, T; Kasai, M; Kobayashi, Y; Matsuno, Y; Miura, I; Mori, S; Morishima, Y; Murayama, T; Nakamura, S; Ogura, M; Ohashi, Y; Sugai, S; Tobinai, K; Uike, N | 1 |
| Błoński, JZ; Chojnowski, K; Kasznicki, M; Robak, T; Szmigielska-Kapłon, A | 1 |
| Ballabeni, P; Cerny, T; Fey, M; Hess, U; Laurencet, F; Luthi, JM; Plancherel, C; Rufener, B; Zulian, GB | 1 |
| Blum, KA; Byrd, JC; Cheson, BD; Johnson, JL; Niedzwiecki, D; Peterson, BA; Piro, LD; Saven, A | 1 |
| Blonski, J; Gora-Tybor, J; Janus, A; Lech-Maranda, E; Robak, T; Wierzbowska, A | 1 |
| Saven, A; Sigal, DS | 1 |
| Ellison, D; Emanuele, S; Kosty, M; Koziol, J; Piro, L; Saven, A | 1 |
| Hiddemann, W; Pott-Hoeck, C | 1 |
| Cheson, BD | 3 |
| Gordon, LI; Hakimian, D; Hoffman, M; Hogan, D; Janson, D; Kuzel, T; Rai, K; Tallman, MS; Variakogis, D | 1 |
| Evans, SS; Messenger, JC; Nagourney, RA; Su, YZ; Weisenthal, LM | 1 |
| Cunningham, D; Dorland, E; Hickish, T; Judson, I; Lister, TA; Millar, BC; Oza, A; Roldan, A; Serafinowski, P | 1 |
| Piro, LD; Saven, A | 1 |
| Alexanian, R; Dimopoulos, MA; Estey, EE; Weber, DM | 1 |
| Hogan, DK; Nelson, MC | 1 |
| Bosly, A; Delannoy, A; Ferrant, A; Filleul, B; Martiat, P; Michaux, JL; Mineur, P; Montfort, L; Straetmans, N; Van Den Neste, E; Vandercam, B | 1 |
| Kosty, M; Lee, T; Piro, L; Saven, A | 1 |
| Piro, LD | 1 |
| Hoffman, MA | 1 |
| Fronczak, A; Góra-Tybor, J; Krykowksi, E; Robak, T; Warzocha, K | 1 |
| Brugiatelli, M; Callea, V; Dmoszynska, A; Holowiecka, B; Holowiecki, J; Jaksic, B; Krieger, O; Labar, B; Lutz, D; Morabito, F; Planinc-Peraica, A | 1 |
| Foss, HD; Knauf, W; Kreuser, ED; Szelényi, H; Thiel, E | 1 |
| Bashford, J; Bunce, I; Dodds, A; Eliadis, P; Firkin, F; Frost, T; Goldstein, D; Grigg, A; Kelly, C; Kimber, R; Lee, N; Lowenthal, R; Moore, D; Morton, J; Mulligan, S; Parkin, J; Rentoul, A; Rodwell, R; Rooney, K; Stone, J; Taylor, K; Wright, S | 1 |
| Bennett, B; Canfield, VA; Guiney, P; Nichols, C; Vose, J | 1 |
| Juliusson, G; Liliemark, J; Porwit, A | 1 |
| Adamczyk-Cioch, MB; Boguradzki, P; Borawska, A; Ceglarek, B; Deren, M; Dmoszyńska, A; Durźyński, T; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Grieb, P; Hellmann, A; Konopka, L; Krykowski, E; Kuratowska, Z; Maj, S; Michalak, K; Opalińska, J; Pluźańska, A; Potemski, P; Róbak, T; Sikorska, A; Urasiński, J; Walewski, JA; Zaucha, JM | 1 |
| Gordon, LI; Hakimian, D; Huang, CF; Klein, L; Kong, LR; Kuzel, TM; Tallman, MS; Variakojis, D; Wollins, E; Zanzig, C | 1 |
| Baudo, F; deCataldo, F; Italia, C; Ottonelli, C; Valdagni, R | 1 |
| Betticher, DC; Cavalli, F; Cerny, T; Egger, T; Fey, MF; Herrmann, R; Kroner, T; Ratschiller, D; Schmitz, SF; Sonderegger, T; von Rohr, A; Zulian, GB | 1 |
| Polliack, A | 1 |
| Cavallin-Ståhl, E; Juliusson, G; Liliemark, J; Martinsson, U; Porwit, A; Strömberg, M; Svedmyr, E | 1 |
| Boswell, W; Espina, BM; Harvey-Buchanan, LA; Khan, AU; Lee, M; Levine, AM; Nathwani, B; Schiller, G; Tulpule, A | 1 |
| Chott, A; Fridrik, MA; Hausmaninger, H; Jäger, G; Kienzer, HR; Krieger, O; Lang, A; Linkesch, W; Neubauer, M; Oppitz, P; Schiller, L; Seewann, HL; Weidinger, G; Zabernigg, A | 1 |
| Arat, M; Beksaç, M; Idilman, R | 1 |
| Gora-Tybor, J; Krykowski, E; Robak, T; Urbańska-Ryś, H | 1 |
| Bergmann, L; Chow, KU; Hansmann, ML; Hoelzer, D; Hossfeld, DK; Jäger, E; Meyer, A; Mitrou, PS; Peters, HD; Rummel, MJ | 1 |
| Alberto, P; Betticher, DC; Guetty-Alberto, M; Iten, PA; Laurencet, FM; Zulian, GB | 1 |
| Aleskog, A; Höglund, M; Kristensen, J; Larsson, R; Sundström, C | 1 |
| Bergmann, L; Chow, KU; Hansmann, ML; Hoelzer, D; Hossfeld, DK; Jäger, E; Leimer, L; Meyer, A; Mitrou, PS; Peters, HD; Rummel, MJ | 1 |
| Balzarotti, M; Bonadonna, G; De Paoli, A; Luoni, M; Rampinelli, I; Santoro, A; Tondini, C; Valagussa, P | 1 |
| André, M; Bosly, A; Coche, E; Delannoy, A; Doyen, C; Duprez, T; Ferrant, A; Louviaux, I; Michaux, JL; Michaux, L; Mineur, P; Sonet, A; Straetmans, N; Van Den Neste, E; Venet, C | 1 |
| Johnson, SA; Thomas, W | 1 |
| Błoński, JZ; Góra-Tybor, J; Kasznicki, M; Lech-Marańda, E; Robak, T | 1 |
| Bartkowiak, J; Błonski, JZ; Kasznicki, M; Kordek, R; Robak, T; Wawrzyniak, E | 1 |
| Beutler, E; Carrera, CJ; Carson, DA; Kay, AC; Piro, LD; Saven, A; Thurston, D | 1 |
12 review(s) available for cladribine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Beyond hairy cell: the activity of cladribine in other hematologic malignancies.
Topics: Antineoplastic Agents; Cladribine; Hematologic Neoplasms; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia | 2010 |
[Cladribine].
Topics: Aged; Antineoplastic Agents; Cladribine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Leukemia, Hairy Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged | 2003 |
Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mitoxantrone; Treatment Outcome | 2004 |
Cladribine in indolent non-Hodgkin's lymphoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Drug Resistance, Neoplasm; Humans; Lymphoma, Non-Hodgkin | 2008 |
Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine | 1995 |
Purine analogs in lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Multiple Myeloma; Pentostatin; Vidarabine | 1993 |
2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies.
Topics: Cladribine; Humans; Leukemia; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous | 1993 |
The role of cladribine in the treatment of lymphoid malignancies.
Topics: Antineoplastic Agents; Cladribine; Drug Monitoring; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Oncology Nursing; Patient Care Planning | 1995 |
Cladribine in the treatment of low-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Waldenstrom Macroglobulinemia | 1996 |
Cladribine for the treatment of indolent non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Waldenstrom Macroglobulinemia | 1996 |
Hairy cell leukemia and allied chronic lymphoid leukemias: current knowledge and new therapeutic options.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cladribine; Diagnosis, Differential; Humans; Interferon-alpha; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Lymphoma, Non-Hodgkin; Pentostatin; Prognosis | 1997 |
Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine | 2000 |
26 trial(s) available for cladribine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2021 |
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cladribine; Female; Humans; Immunologic Factors; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; Salvage Therapy; Time Factors; Treatment Outcome | 2011 |
Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prospective Studies; Treatment Outcome | 2002 |
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
Topics: Adult; Aged; Cladribine; Female; Humans; Japan; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis | 2004 |
Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Etoposide; Female; Humans; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Hematologic Diseases; Humans; Immunocompromised Host; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
Topics: Adolescent; Adult; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2006 |
Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Feasibility Studies; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Anemia; Cladribine; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Survival Rate; Thrombocytopenia; Time Factors | 1995 |
2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.
Topics: Adult; Aged; Cladribine; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1993 |
2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Cladribine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Survival Rate; Time Factors | 1996 |
2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cladribine; Disease-Free Survival; Female; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Treatment Outcome | 1997 |
Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma.
Topics: Cladribine; Disease Progression; Dose-Response Relationship, Drug; Humans; Infections; Leukopenia; Lymphoma, Non-Hodgkin; Survival Rate; Thrombocytopenia | 1997 |
Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Retreatment | 1997 |
Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Infections; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Prognosis; Survival Analysis; Treatment Outcome | 1998 |
Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Drug Administration Schedule; Female; Humans; Immunocompromised Host; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Opportunistic Infections; Prospective Studies; Remission Induction; Risk; Statistics, Nonparametric; Survival Analysis | 1998 |
Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Transformation, Neoplastic; Cladribine; Disease Progression; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Middle Aged; Platelet Count; Survival Analysis; Thrombocytopenia; Treatment Outcome | 1998 |
Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate | 1998 |
Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease Progression; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Failure | 1998 |
Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Dexamethasone; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction | 1999 |
Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.
Topics: Aged; Antineoplastic Agents; Cladribine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Recurrence; Survival Rate; Treatment Outcome | 1999 |
Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Germany; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Recurrence; Remission Induction; Treatment Outcome | 1999 |
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Confidence Intervals; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine | 2000 |
Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis | 2000 |
Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Treatment Outcome | 2001 |
2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Topics: 2-Chloroadenosine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bacterial Infections; Bone Marrow Diseases; Cladribine; Deoxyadenosines; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Treatment Outcome | 1992 |
22 other study(ies) available for cladribine and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Retrospective Studies; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine | 2012 |
Development of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma 13 years after treatment with cladribine.
Topics: Antineoplastic Agents; Cladribine; Female; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Middle Aged | 2013 |
Successful treatment with 2-chlorodeoxyadenosine of secondary lesions of the central nervous system in low-grade lymphoid malignancies.
Topics: Central Nervous System Neoplasms; Cladribine; Disease-Free Survival; Female; Humans; Leukemia, Hairy Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasms, Second Primary; Treatment Outcome; Waldenstrom Macroglobulinemia | 2002 |
2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma.
Topics: Adult; Castleman Disease; Cladribine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Treatment Outcome | 2003 |
Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Cladribine; Gastrointestinal Neoplasms; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Myelodysplastic Syndromes | 2004 |
2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Cladribine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy; Treatment Outcome | 1994 |
2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms.
Topics: Cladribine; Cytarabine; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Leukemia; Lymphoma, Non-Hodgkin; Mechlorethamine; Multiple Myeloma; Protein Binding; Tumor Cells, Cultured; Vincristine | 1993 |
Primary treatment with 2-chlorodeoxyadenosine of low grade lymphomas that produce IgG or IgA immunoglobulin.
Topics: Adult; Aged; Cladribine; Female; Humans; Immunoglobulin A; Immunoglobulin G; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1993 |
Infectious complications after 2-chlorodeoxyadenosine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Cohort Studies; Disease Susceptibility; Female; Fever; Hematologic Diseases; Herpesviridae Infections; Humans; Immunologic Deficiency Syndromes; Incidence; Infections; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Risk Factors; Waldenstrom Macroglobulinemia | 1996 |
Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone | 1996 |
Fulminant 2-chlorodeoxyadenosine-related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma.
Topics: Adult; Antineoplastic Agents; Cladribine; Humans; Lymphoma, Non-Hodgkin; Male; Paraneoplastic Syndromes; Peripheral Nervous System Diseases | 1996 |
Fatal Mucor pneumonia after treatment with 2-chlorodeoxyadenosine for non-Hodgkin's-lymphoma.
Topics: Aged; Cladribine; Fatal Outcome; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Mucormycosis; Pneumonia | 1996 |
High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Opportunistic Infections; Recurrence; Survival Analysis; Thrombocytopenia; Treatment Outcome | 1996 |
Complete regression of a suprasellar secondary mass in a patient with low-grade non-Hodgkin's lymphoma (NHL) treated with 2-chlorodeoxyadenosine (CdA)
Topics: Antineoplastic Agents; Brain Neoplasms; Cause of Death; Cladribine; Fatal Outcome; Female; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Remission Induction; Tomography, X-Ray Computed | 1998 |
New prospects in the treatment of indolent lymphomas with purine analogues.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1998 |
Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction | 1999 |
Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Drug Administration Schedule; Feasibility Studies; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Waldenstrom Macroglobulinemia | 1999 |
Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA.
Topics: Acute Disease; Antineoplastic Agents; Cladribine; Cytarabine; Fluorescence; Fluorometry; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Survival Analysis; Vidarabine | 1999 |
Richter's syndrome following cladribine therapy for chronic lymphocytic leukemia first manifested as pathologic fracture of the femur.
Topics: Aged; Bone Marrow; Cell Transformation, Neoplastic; Cladribine; Femoral Fractures; Humans; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary; Radionuclide Imaging; Syndrome | 2001 |
The purine analogs--a therapeutic beauty contest.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Deoxyadenosines; Humans; Leukemia; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1992 |
Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Deoxyadenosines; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1992 |